Endothelin (ET)-1 is an important peptide in cancer progression stimulating cellular proliferation, tumor angiogenesis and metastasis. ET-1 binds with high affinity to the ET A receptor (R) and ET B R on cancer cells. High levels of tumor ET-1 and ET A R are associated with poor survival of lung cancer patients. Here the effects of ET-1 on epidermal growth factor (EGF)R and HER2 transactivation were investigated using nonsmall cell lung cancer (NSCLC) cells. ET A R mRNA was present in all 10 NSCLC cell lines examined. Addition of ET-1 to NCI-H838 or H1975 cells increased EGFR, HER2 and ERK tyrosine phosphorylation within 2 min. The increase in EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells was inhibited by lapatinib (EGFR and HER2 tyrosine kinase inhibitor (TKI)), gefitinib (EGFR TKI), ZD4054 or BQ-123 (ET A R antagonist), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor) or Tiron (superoxide scavenger). ET-1 addition to NSCLC cells increased cytosolic Ca 2+ and reactive oxygen species. ET-1 increased NSCLC clonal growth, whereas BQ123, ZD4054, lapatinib or gefitinib inhibited proliferation. The results indicate that ET-1 may regulate NSCLC cellular proliferation in an EGFR-and HER2-dependent manner.
Introduction
Endothelin (ET) peptides ET-1, ET-2 and ET-3 have 21 amino acids and two disulfide bonds. The structures of ET-2 and ET-3 differ by 2 and 6 amino acids, respectively, from ET-1 [20] . ET-1 is metabolized by neutral endopeptidase from a 212 amino acid prepro-ET-1 to big-ET-1 containing 38 amino acids. Big ET-1 is subsequently metabolized by endothelin converting enzyme (ECE-1) to ET-1 [41] . ET-1 is present in many human cancer cell lines derived breast, colon, lung, prostate and stomach cancer [1, 22, 31] ET-1 is overexpressed in breast, colorectal, lung and ovarian tumors [4, 7] . ET-1 is an important factor in tumor progression stimulating cellular proliferation, tumor angiogenesis and bone metastasis [4, 15, 30] .
ET-1 and ET-2 but not ET-3 binds with high affinity to the ET A R [17] . In contrast, ET-1, ET-2 and ET-3 bind with high affinity to the ER B R [2] . BQ788 is a selective ET B R antagonist where BQ123, ZD4054 and atrasentan are selective ET A R antagonists [5] . The mitogenic effects of ET-1 are mediated by the ET A R [38] . When ET-1 binds to ET A R, G proteins are activated resulting in stimulation of phospholipase C and D, phospholipase (PL) A 2 , adenylylcyclase and/or guanylylcyclase [39] . Phospholipase C metabolizes phosphatidylinositol-4,5-diphosphate (PIP 2 ) to diacylglycerol (activates protein kinase C) and inositol-1,4,5-trisphosphate (elevates cytosolic Ca 2+ ) leading to Src activation [18] . ET-1 elevates cytosolic Ca 2+ in lung cancer cells and stimulates their proliferation [43] . ET-1 causes transactivation of receptor tyrosine kinases (RTK) such as the EGFR and PDGF receptor [13, 37, 40, 42] . The RTK activates the Ras, Raf, MEK, ERK pathway allowing phosphorylated ERK to enter the nucleus and increase expression of fos, jun and myc [6] .
ET-1 mRNA was detected in 6/7 small cell lung cancer (SCLC) and 4/4 non-SCLC (NSCLC) cell lines [1] . NSCLC, which accounts for approximately 80% of the lung cancer cases is comprised of adenocarcinoma (Ad), large cell carcinoma (LC) and squamous cell carcinoma (Sq). ET-1 immunoreactivity was detected in 24 of 36 NSCLC biopsy specimens but only 2 of 12 SCLC tissues [14] . Similarly, big ET-1 was detected in lung cancer biopsy specimens and plasma [3] . ET-1 expression in lung tumors is associated with poor patient overall survival and decreased disease-free survival [7] . ET-1 may be an autocrine growth factor in lung cancer. In this communication, the effects of ET-1 were investigated on non-small cell lung cancer (NSCLC) cells. It is unknown if the ET A R regulates EGFR and HER-2 transactivation in NSCLC. A hypothesis is that ET-1 regulates NSCLC cellular proliferation in an EGFR and HER2-dependent manner.
Materials and methods

Cell culture
Human SCLC cell lines (ATCC, Manassas, VA) were cultured as floating aggregates and were split 1:1 weekly in Roswell Park Memorial Institute (RPMI)-1640 medium containing 10% fetal bovine serum (FBS Invitrogen, Grand Island, NY). Human NSCLC cells (ATCC, Manassas, VA) were adherent and were treated with trypsin-EDTA after washing with PBS. After detachment from the flask, the cells were treated with an equal volume of RPMI-1640 with 10% FBS. The cells were centrifuged at 1000 × g for 5 min and resuspended 1:20 in a T175 flask. The cells were mycoplasma free and were used when they were in exponential growth phase after incubation at 37 • C in 5%CO 2 /95% air.
RT-PCR
Total RNA was isolated from frozen pellets of lung cancer cells. Total RNA was prepared using a RNeasy Mini Kit (Qiagen, Valencia, CA). RNA samples were treated with DNase Digestion (Qiagen, Valencia, CA) during preparation to remove contaminating DNA. Total RNA (1 g) was reverse-transcribed using a Super ScriptRM III First-Strand Synthesis SuperMix for the qRT-PCR (Invitrogen, Waltham, MA) according to the manufacturer's instructions for complementary DNA (cDNA) synthesis. One microliter of the RT reaction mix containing cDNA was amplified using EDNRA-S2 and EDNRB-S1 PCR in a reaction mixture containing HotStar TaqR Master Mix Kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. Amplification was performed for the ET A R using the following: Forward primer is 5 TCTGTATGCCCTTGGTGTGC-3 and the reverse primer is 5 CCACTTCTCGACGCTGCTTA-3 . For the ET B R, the forward primer is 5 -CTTGCCATTGGCCATCACTG-3 and the reverse primer is 5 -CCACTTCCCGTCTCTGCTTT-3 . Amplification for all PCR reactions included an initial cycle of 95 • C for 15 min, followed by 35 cycles of denaturation at 94 • C for 30 s, annealing at 60 • C for 30 s and extension at 72 • C for 1 min. After the final cycle, all PCR reactions were concluded with a 10 min extension at 72 • C. The PCR products were analyzed on a 3% agarose gel and visualized by ethidium bromide staining.
Receptor binding
For the radioreceptor assay, NCI-H838 or H1975 cells were placed in 24 well plates. 125 I ET-1 (2200 Ci/mmol) was prepared using 0.8 g iodogen in 100 l of 0.5 M KH 2 PO 4 (pH 8.0), 10 g ET-1 and 2 mCi 125 I. After 6 min free 125 I was removed after application to a Sep-Pak and washing with 5 ml of 0.1% trifluoroacetic acid (TFA). 125 I ET-1 was eluted with 5 ml of 60% acetonitrile in 0.1%TFA. 125 I ET-1 was further purified by HPLC using a Bondapak column from Waters Corporation. The purified 125 I ET-1 was stored in 0.5% BSA at −20 • C until use. Confluent cells were washed 3 times in SIT medium (RPMI-1640 containing 3 × 10 −8 M sodium selenite, 5 g/ml bovine insulin and 10 g/ml transferrin (Sigma-Aldrich, St. Louis, MO)). The cells were incubated in SIT buffer containing 0.25% bovine serum albumin and 250 g/ml bacitracin (Sigma-Aldrich, St. Louis, MO) and 125 I ET-1 (100,000 cpm) added as well as various concentrations of ET-1, ET-3, ZD-4504, BQ123 or BQ788. After incubation at 37 • C, for 30 min, free 125 I ET-1 was removed by washing 3 times in buffer and the cells which contained bound 125 I ET-1 dissolved in 0.2 N NaOH and counted in a gamma counter. The IC 50 was calculated for each unlabeled competitor.
Western blot
The ability of ET-1 (Bachem Inc., Torrence, CA) to stimulate tyrosine phosphorylation of the EGFR, HER2 or ERK (p42/p44 MAP kinase) was investigated by Western blot. NCI-H838 or NCI-H1975 cells were placed in 10 cm dishes and when confluent they were placed in SIT media for 3 h. Routinely, NSCLC cells were treated with ZD4054 (ApexBio, Houston, TX), gefitinib (Tocris Bioscience, Bristol, UK), BQ123 (Tocris Brioscience, Bristol, UK), BQ788 (Tocris Bioscience, Bristol, UK), PP2 (Sigma-Aldrich, St. Louis, MO), GM6001 (Sigma-Aldrich, St. Louis, MO), Tiron (Sigma-Aldrich, St. Louis, MO) or no additions for 30 min. Then cells were incubated with 0.1 M ET-1 for 2 min, washed twice with PBS and lysed in buffer containing 50 mM Tris.HCl (pH 7.5), 150 mM sodium chloride, 1% Triton X-100, 1% deoxycholate, 1% sodium azide, 1 mM ethyleneglycoltetraacetic acid, 0.4 M EDTA, 1.5 mg/ml aprotinin, 1.5 mg/ml leupeptin, 1 mM phenylmethylsulfonylfluoride and 0.2 mM sodium vanadate (Sigma-Aldrich, St. Louis, MO). The lysate was sonicated for 5 s at 4 • C and centrifuged at 10,000 × g for 15 min. Protein concentration was measured using the BCA reagent (Pierce Chemical Co., Rockford, IL), and 400 mg of protein was incubated with 4 mg of anti-phosphotyrosine (PY) monoclonal antibody (BD Biosciences), and 15 ml of immobilized protein G (Pierce Chemical Co., Rockford, IL) overnight at 4 • C. The immunoprecipitates were washed 3 times with phosphate buffered saline and analyzed by sodium dodecyl sulfate/polyacrylamide gel electrophoresis and Western blotting. Immunoprecipitates were fractionated using 4-20% polyacrylamide gels (Novex, San Diego, CA). Proteins were transferred to nitrocellulose membranes as described previously [29] . After washing the blot was incubated with enhanced chemiluminescence detection reagent for 5 min and exposed to Biomax XAR film (Carestream, Rochester, NY). The band intensity was determined using a densitometer.
Alternatively, 20 g of cellular extract was loaded onto a 15 well 4-20% polyacrylamide gels. After transfer to nitrocellulose, the blot was probed with anti PY 1068 -EGFR, anti EGFR, anti PY 204 ERK, anti ERK, anti PY 1244 -HER2, anti-HER2 or anti-tubulin (Cell Signaling Technologies, Danvers, MA).
Cytosolic Ca 2+
NCI-H838 or H1975 cells were treated with trypsin-EDTA and harvested. After centrifugation the cells were resuspended in SIT medium (2.5 × 10 6 cells/ml) containing Fura-2AM (Calbiochem, La Jolla, CA) at 37 • C for 30 min [29] . The cells were centrifuged at 1000 × g for 5 min and resuspended at a concentration of 2.5 × 10 6 /ml and 2 ml placed in a Quartz cuvette containing a stirbar. The excitation ratio was determined at 340 and 380 nm and the emission at 510 nm using a spectrofluorometer equipped with a magnetic stirring mechanism and temperature (37 • C) regulated cuvette holder before and after addition of ET-1.
Reactive oxygen species
NCI-H838 cells were placed in black 96 well plates (30,000 cells/well) and cultured overnight. The cells were treated with 10 M dichlorofluorescein diacetate (H2DCF) for 1 h and washed 3 times with serum-free SIT medium. Some of the cells were treated with 10 M ZD4054 or 5 mM Tiron for 30 min and then stimuli such as 10 nM ET-1 or 10 M H 2 O 2 added. Fluorescence measurements were taken at the various times using an excitation wavelength of 485 nm and emission wavelength of 585 nm. 
Proliferation
Growth studies in vitro were conducted using the 3-(4,5-dimethylthiazol-2-yl)-2.5-diphenyl-2H-tetrazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO) and clonogenic assays. In the MTT assay, A549, NCI-H727 or H838 cells were placed in SIT medium and various concentrations of ZD4054, lapatinib or trastuzumab (Sigma-Aldrich, St. Louis, MO) added. After 2 days, 15 l of 0.1% MTT solution added. After 4 h, 150 ml of dimethylsulfoxide was added and the optical density at 570 nm was determined. In the clonogenic assay, the effects of ET-1, BQ123, BQ788 and gefitinib were investigated on NCI-H838 cells. The bottom layer contained 0.5% agarose in SIT medium containing 5% FBS in 6 well plates. The top layer consisted of 3 ml of SIT medium in 0.3% agarose, ET-1, BQ788, BQ123 and/or gefitinib using 5 × 10 4 lung cancer cells. Triplicate wells were plated and after 2 weeks, 1 ml of 0.1% p-iodonitrotetrazolium violet was added and after 16 h at 37 • C, the plates were screened for colony formation; the number of colonies larger than 50 m in diameter were counted using an Omnicon image analysis system.
Statistical analysis
The results are expressed as means ± S.D. Statistical significance of differences was performed by one-way or two-way repeated measures analysis of variance.
Results
ET A R and ET B R mRNA are present in NSCLC cells
ET A R and ET B R were investigated in SCLC and NSCLC cells. Fig. 1 shows that ET A R PCR-products were present in all 10 NSCLC cells tested (NCI-H157 (Sq), H358 (Ad), H460 (LC), H520 (Sq), A549 (Ad), H838 (Ad), H1299 (LC), H1975 (Ad), H1650 (Ad) and SK-LU-1 (Ad) where ET B R mRNA was present in 8 NSCLC cell lines tested but not H358 or H1975. ET A R mRNA was present in 5 SCLC cells lines (NCI-H82, H209, H345, N417 and H510) but not H69. ET B R mRNA was detected only in SCLC cell lines NCI-H82 and H510 cell lines. ET A R and ET B R mRNA were detected in 2 lung carcinoid cell lines (NCI-H720 and H727) as well as a mesothelioma cell line NCI-H28. As a control, equal amounts on ␤-actin mRNA were detected in the cells. Densitometry analysis indicated that ET A R mRNA was highest in NCI-H358 and H1975, whereas ET B R mRNA was highest in SK-LU-1. In general, Ad, LC and Sq NSCLC cells were enriched in ET A R mRNA relative to ET B R mRNA.
ET A R binding sites are present in NSCLC cells
The ability of ET-1, ET-3, BQ123, BQ788 and ZD4054 to inhibit specific 125 I ET-1 binding to NSCLC cell lines was investigated. Fig. 2A shows that ET-1 strongly but ET-3 weakly inhibited specific 125 I ET-1 binding to NCI-H838 cells (IC 50 = 0.2 and >1000 nM, respectively). Similarly, BQ123 and ZD4054 inhibited specific 125 I ET-1 binding with high affinity (IC 50 = 1 and 0.5 nM respectively) whereas BQ788 was less potent (IC 50 = 20 nM). Table 1 shows that the order of binding potency for both NCI-H838 and NCI-H1975 cells is ET-1 > ZD4054 = BQ123 > BQ788 > ET-3, gefitinib or lapatinib. The results indicate that ET-1 is primarily binding to ET A R on NCI-H838 and H1975 cells.
ET-1 increases cytosolic calcium which is blocked by ET A R antagonists
The ability of ET-1 to increase cytosolic Ca 2+ was investigated in NSCLC cells. Addition of 10 nM ET-1 to NCI-H1975 cells increased rapidly the cytosolic Ca 2+ within seconds from 150 to 180 nM (Fig. 2B, I ). The cytosolic Ca 2+ slowly declined and return to baseline by 2 min. Addition of 1000 nM BQ123 did not alter the cytosolic Ca 2+ but blocked the ability of 10 nM ET-1 to increase Ca 2+ in NCI-H1975 cells (Fig. 2B, II) . The effects of BQ123 were reversible in that addition of 1000 nM ET-1 increased the Ca 2+ (Fig. 2B, IV) . Addition of 1000 nM BQ788 had no effect on cytosolic Ca 2+ and did not antagonize the ability of 10 nM ET-1 to increase Ca 2+ (Fig. 2B, III) . Similar data were obtained using NCI-H838 cells (T. Moody, unpublished). The results indicate that the ET A R regulates cytosolic Ca 2+ in NSCLC cells.
ET-1 causes increases protein tyrosine phosphorylation in NSCLC cells
The ability of ET-1 to cause transactivation of the EGFR was investigated using NSCLC cells. Fig. 3A shows that 2 min after addition of 1 nM ET-1 to NCI-838 cells, the EGFR tyrosine phosphorylation was moderately increased whereas 10 nM, 100 nM or 1000 nM ET-1 increased strongly EGFR transactivation. Fig. 3B shows that 1 nM ET-1 increased EGFR tyrosine phosphorylation significantly to 149% whereas 10 nM, 100 nM or 1000 nM ET-1 increased EGFR tyrosine phosphorylation significantly to approximately 340%. The half maximal dose of ET-1 to increase EGFR tyrosine phosphorylation (ED 50 ) was 3 nM. As a control, ET-1 had little effect on total EGFR. ET-1 addition to NCI-H838 cells at all doses tested increased tyrosine phosphorylation of ERK (Fig. 3A) . ET-1 at a 1 nM dose significantly increased tyrosine phosphorylation of ERK to 161% whereas 10 nM, 100 nM or 1000 nM ET-1 increased significantly ERK tyrosine phosphorylation to approximately 190% (Fig. 3B) . As a control, ET-1 had little effect on total ERK. The results indicate that ET-1 addition to NSCLC cells increases EGFR and ERK tyrosine phosphorylation in a dose-dependent manner.
ET-1 causes EGFR and HER2 transactivation
The effects of ET A R antagonists and TKI were investigated on EGFR and HER2 transactivation. Fig. 4A shows that addition of 100 nM ET-1 to NSCLC cells increased significantly tyrosine phosphorylation of the EGFR and HER2. BQ123 in a dose-dependent manner inhibited the EGFR and HER2 transactivation caused by ET-1 addition to NSCLC cells. Fig. 4B shows that 100 nM ET-1 increased EGFR and HER2 tyrosine phosphorylation significantly to 360 and 280%, respectively. BQ123 had little effect at 0.1 M whereas 1 M or 10 M BQ123 significantly reduced EGFR and HER2 tyrosine phosphorylation that was regulated by the ET A R. Similarly, ZD4054 inhibited whereas BQ788 had little effect on the ability of ET-1 to increase EGFR or HER2 transactivation (data not shown). Fig. 4C shows that 10 g/ml but not 1 g/ml gefitinib significantly reduced the ability of ET-1 to cause EGFR and HER2 transactivation. Fig. 4D shows that ET-1 significantly increased EGFR and HER2 phosphorylation by 355% and 308%, respectively and that 10 g/ml gefitinib significantly inhibited the increase caused by ET-1. Similarly, lapatinib (EGFR and HER2 TKI) inhibited the ability of the ET A R to regulate EGFR and HER2 transactivation (data not shown). As a control, ET-1 had no effect on total EGFR or HER2. The results suggest that the ET A R regulates the ability of the EGFR to form homodimers with itself or heterodimers with HER2.
Inhibitors of EGFR and HER2 transactivation caused by ET-1
The ability of other agents to impair the ET A R regulation of EGFR and HER2 tyrosine phosphorylation was investigated. Fig. 5A shows that ET-1 addition to NSCLC cells significantly increased EGFR and HER2 phosphorylation which was inhibited by PP2 (Src inhibitor) or GM6001 (MMP inhibitor). Fig. 5B shows that ET-1 addition to NSCLC cells increased EGFR and HER2 phosphorylation significantly to 322 and 288%, respectively, and this increase was inhibited significantly by addition of PP2 or GM6001 to NSCLC cells. Fig. 5C shows that ET-1 addition to NSCLC cells increased EGFR and HER2 tyrosine phosphorylation significantly to 348 and 275% significantly and that this increase was inhibited significantly by Tiron, a superoxide scavenger. As a control, PP2, GM6001 or Tiron had no effect on basal P-EGFR, EGFR, P-HER2 or HER2 (data not shown). Table 2 shows that addition of ET-1 or H 2 O 2 to NSCLC cells increased reactive oxygen species (ROS). The increase in ROS caused by ET-1 or H 2 O 2 was significantly inhibited by Tiron. The increase in ROS cause by ET-1, but not H 2 O 2, was significantly inhibited by ZD4054. The results indicate that the ET A R regulates ROS produced by ET-1.
Proliferation of NSCLC cells
The ability of ET A R antagonists and TKI to inhibit the proliferation of NSCLC cells was investigated. Fig. 6A shows that using the MTT assay, lapatinib inhibits the proliferation of NSCLC cells in a dose-dependent manner. For NCI-H727, H838 and A549 cells the IC 50 for lapatinib was 0.5, 1 and 2 g/ml, respectively. Trastuzumab inhibited proliferation of NCI-H727, H838 and A549 cells with IC 50 values of 0.5, 1 and 2 g/ml (Fig. 6B) . For NCI-H727, H838 and A549 cells, the IC 50 for ZD4054 was 30, 50 and 45 g/ml, respectively (Fig. 6C) . The results indicate that HER2 inhibitors and ET A R antagonists inhibit the proliferation of NSCLC cells. Using the clonogenic assay, 10 nM ET-1 increased significantly the clonal growth of NCI-H838 cells to 150% (Table 3 ). In contrast, 1 M BQ123 but not BQ788 reduced significantly NSCLC colony number in the presence or absence of exogenous ET-1. BQ123 and gefitinib reduced significantly the NSCLC colony number by 22 and 50%, respectively in the absence of exogenous ET-1. Addition of both BQ123 and gefitinib reduced significantly NSCLC colony number to approximately 10%. The results indicate that ET-1 stimulates, whereas BQ123 and gefitinib inhibit NSCLC proliferation.
Discussion
NSCLC patients are traditionally treated with combination chemotherapy, however, the five year survival rate is only 16% [19] . Approximately 13% of the NSCLC patients have EGFR mutations such as L858R and these patients initially respond to the TKI such as erlotinib or gefitinib [25, 32] . Subsequently NSCLC patients become resistant to erlotinib or gefitinib due to secondary EGFR mutations such as T790 M [24] . It is important to increase the sen- sitivity of TKI in NSCLC patients with wild type EGFR or secondary T790 M mutations. Increased expression of HER2 occurs in approximately 20% of the NSCLC patients [26] . Breast cancer patients with overexpressed HER2 are treated with lapatinib (TKI) or Herceptin [trastuzumab; 16] . Ligands which activate HER2 have not been identified, whereas numerous ligands activate the EGFR such as amphiregulin, EGF, heparin binding EGF (HB-EGF) or TGF␣ [33] . Previously, we found that when GPCRs were activated, TGF␣ is released from NSCLC cells [28, 29] . The TGF␣ activates the EGFR resulting in EGFR homodimers or EGFR-HER2 heterodimers [23] .
ET A R mRNA is present in many lung cancer cells [1] . ET A R mRNA was significantly elevated in NSCLC biopsy specimens relative to normal lung tissue [7] . ET-1 or ET A R expression is associated with poor survival of NSCLC patients. In clinical studies, the ET A R antagonist atrasentan plus paclitaxel-carboplatin was well tolerated, however, efficacy and survival in NSCLC patients was similar to patients treated with chemotherapy alone [9] . Similarly, no differences were observed in overall survival of NSCLC patients treated with zibotentan (ZD4054) or zibotentan plus pemetrexed [10] . In contrast, ZD4054 is synergistic with gefitinib at inhibiting ovarian cancer growth and invasion [36] . Macitentan, a dual ET A R and ET B R antagonist, in combination with temozolomide inhibits glioblastoma growth in animal models [21] . The results suggest that ET A R regulates cancer proliferation and metastasis.
ET A R mRNA was detected in all NSCLC cell lines examined as well as most SCLC, lung carcinoids and a mesothelioma cell line (Fig. 1) . Specific 125 I ET-1 binding to NSCLC cells was inhibited with high affinity by ET-1 and ET A R antagonists, but not ET-3 ( Fig. 2A) . These results suggest the ET A R predominates over ET B R in NSCLC cells. ET-1 addition to NSCLC cells increased cytosolic Ca 2+ from 150 to 180 nM, which was inhibited by BQ123 but not BQ788 (Fig. 2B) . Similarly, ET-1 addition to NSCLC cell line SC-A1 increased cytosolic Ca 2+ by 32 nM and the increase caused by ET-1 was reversed by BQ123, U73122 (PLC inhibitor) and nifedipine [Ca 2+ channel blocker; 43]. These results demonstrate that the ET A R in NSCLC regulates PI turnover and the resulting IP 3 causes increased cytosolic Ca 2+ .
In both normal and malignant cells, the ET A R regulates EGFR transactivation [13, 40] . Activation of the ET A R increases release of EGFR ligands such as HB-EGF [33] . The increase in EGFR transactivation caused by ET-1 addition to ovarian cancer cells is blocked by ZD4054 (ET A R antagonist) or gefitinib [TKI, 36] . Addition of ET-1 to NSCLC cells increased EGFR and HER2 transactivation which was inhibited by BQ123 or gefitinib (Fig. 4) . ET-1 signaling stimulates ovarian cancer cellular proliferation via the scaffold protein ␤-arrestin [35] . ␤-Arrestin regulates Wnt signaling resulting in nuclear accumulation of ␤-catenin where it promotes histone deacetylase dissociation and the recruitment of p300 acetyltransferase [34] . This alters the expression of numerous genes such as ET-1, axin 2, MMP2 and cyclin D1. ET-1 signaling is impaired by siRNA to ␤-arrestin1 or the mixed ET A R/ET B R antagonist maciten-tan [21] . It remains to be determined if ET-1 stimulates lung cancer proliferation in a ␤-arrestin-dependent manner.
EGFR transactivation caused by addition of ET-1 is dependent on generation of ROS, which may reduce essential disulfide bonds impairing phosphotyrosine. phosphatase activity [8] . Treatment of NSCLC cells with N-acetylcysteine (antioxidant) or Tiron (superoxide scavenger) inhibited the ability of ET-1 to cause EGFR or HER-2 transactivation.
ET-1 addition to ovarian cancer cells increased EGFR transactivation and ovarian cancer cellular proliferation which was inhibited by ZD4054 or gefitinib [36] . Gefitinib plus ZD4054 significantly increased apoptosis of ovarian cancer cells relative to gefitinib or ZD4054 alone. Treatment of ovarian cancer cells with ZD4054 or siRNA to the ET A R significantly increased E-cadherin expression, suggesting inhibition of the ET A R impairs epithelial to mesenchymal transitions [37] . Gefitinib and ZD4054 are synergistic at inhibiting ovarian cancer proliferation, invasion and VEGF production. BQ123 or gefitinib inhibited significantly NSCLC proliferation, whereas ET-1 stimulated the growth of NSCLC cells (Table 3 ). Because BQ788 had little effect on NSCLC growth, the ET A R is important in NSCLC proliferation. Furthermore, the growth inhibitory effects of ZD4054 plus gefitinib are greater than either agent alone. It remains to be determined if gefitinib and ET A R antagonists synergistically inhibit NSCLC growth in vivo.
A surprising finding is that addition of ET-1 to NSCLC cells causes transactivation of HER2. The transactivation of the EGFR and HER2 caused by ET-1 addition to NSCLC cells is blocked by BQ123 (ET A R antagonist), gefitinib (EGFR TKI), PP2 (Src inhibitor), GM6001 MMP inhibitor) and Tiron (superoxide scavenger). The results suggest that ET-1 addition to lung cancer cells causes the formation of EGFR homodimers and EGFR/HER2 heterodimers. Preliminary data indicate that HER2 and EGFR mRNA is present in all NSCLC cell lines examined (P. Moreno, unpublished). HER2 is overexpressed in 20% and mutated in 2% of the lung cancer specimens examined [11] . Treatment of lung cancer patients who have HER2 mutations with trastuzumab resulted in a 51% overall response rate [27] . Afatinib, a second generation TKI, inhibits the growth of lung Ad patients with HER2 mutations [12] . It remains to be determined if ET A R antagonists or miRNA to ET-1 or the ET A R potentiate the ability of trastuzumab to inhibit lung cancer growth.
In summary, ET-1 addition to NSCLC cells increases EGFR, ERK and HER2 tyrosine phosphorylation as a result of activation of the ET A R. ET-1 addition to NSCLC cells increases ROS leading to increased proliferation. The proliferation of NSCLC cells is inhibited by gefitinib or lapatinib (TKI) as well as BQ123 or ZD4054 (ET A R antagonist). The results suggest that ET-1 may stimulate NSCLC proliferation as a result of the formation of EGFR homodimers or EGFR-HER2 heterodimers.
